Table 1 Patient characteristics
Age at PCa diagnosis | Median (range) |
|---|---|
64 (48–78) | |
Initial T-stage | n (%) |
T2a/b | 6 (7.7) |
T2c | 22 (28.2) |
T3a | 18 (23.1) |
T3b | 32 (41.0) |
Initial N stage | n (%) |
N0 | 62 (79,5) |
N1 | 16 (20,5) |
Surgical margins | n (%) |
R0 | 48 (61,5) |
R1 | 30 (38,5) |
Initial risk group | n (%) |
Intermediate | 3 (3.9) |
High | 29 (37.2) |
Very high | 46 (58.8) |
Initial PSA (ng/ml) | Median (range) |
11.4 (2.8–231.0) | |
First PSA after RP (ng/ml) | Median (range) |
0.07 (0.0–1.9) | |
Interval in months from RP to sRT | Median (range) |
11.16 (3.1–172.6) | |
PSA nadir after sRT (ng/ml) | Median (range) |
0.84 (0.0–12.2) | |
Interval in months from sRT to PSA recurrence | Median (range) |
22.7 (3.0–136.6) | |
Biochemical non-response after sRT | n (%) |
4 (5.1) | |
PSA level at PSMA-PET imaging (ng/ml) | Median (range) |
1.9 (0.1–22.1) | |
Patients with ADT at PSMA-ligand PET imaging | n (%) |
3 (3.9) | |
PSA-dt at time of PSMA-PET imaging (months) | n (%) |
< 3 (n) | 3 (3.9) |
3–6 (n) | 32 (41.0) |
> 6–12 (n) | 23 (29.5) |
> 12 (n) | 16 (20.5) |
unknown | 4 (5.1) |